ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-5

ENDOCRINE PERTURBATIONS INDUCED BY ADJUVANT CHEMOTHERAPY IN NON-LUMINAL B BREAST CANCER WITH LYMPH NODE INVOLVEMENT POST-ORGAN-PRESERVING SURGERY

SOBIRJONOVA Z.A, IKROMOVA G.N, QADAMBOY M.M, MALIKOVA L.N

Department of General Oncology, first-year master's students

TASHKENT STATE MEDICAL UNIVERSITY

ABSTRACT

Adjuvant chemotherapy is integral to the management of non-luminal B breast cancer subtypes—luminal A, HER2-positive, and triple-negative breast cancer (TNBC)—with lymph node involvement following organ-preserving surgery. This study elucidates the multifaceted endocrine disruptions precipitated by cytotoxic regimens, including cyclophosphamide, methotrexate, and fluorouracil (CMF), anthracyclines, and taxanes, focusing on ovarian function, hormonal homeostasis, and skeletal integrity. In premenopausal women, chemotherapy frequently induces premature ovarian insufficiency (POI), characterized by elevated follicle-stimulating hormone (FSH), diminished estradiol, and resultant amenorrhea, with profound implications for fertility and quality of life. Gonadotropin-releasing hormone (GnRH) agonists mitigate these effects by suppressing ovarian activity. In postmenopausal women, chemotherapy synergizes with aromatase inhibitors (AIs) to exacerbate bone mineral density (BMD) loss, elevating fracture risk. This review integrates molecular, clinical, and epidemiological data to delineate these endocrine sequelae, emphasizing personalized therapeutic strategies, fertility preservation, and bone health interventions. Two tables summarize key endocrine outcomes and management approaches, underscoring the necessity for tailored survivorship care in this cohort.

Keywords: Non-luminal B breast cancer, adjuvant chemotherapy, premature ovarian insufficiency, endocrine disruption, lymph node involvement, organ-preserving surgery, gonadotropin-releasing hormone agonists, bone mineral density, fertility preservation, aromatase inhibitors

INTRODUCTION

Breast cancer exhibits molecular heterogeneity, classified into subtypes based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Non-luminal B subtypes—luminal A (ER/PR-positive, HER2-negative, low Ki-67), HER2-positive (HER2-overexpressed, ER/PR-variable), and triple-negative breast cancer (TNBC; ER/PR/HER2-negative)—present distinct therapeutic challenges, particularly in node-positive cases following organ-preserving surgery (e.g., lumpectomy). Adjuvant chemotherapy, employing regimens such as CMF, anthracyclines (e.g., doxorubicin), and taxanes (e.g., paclitaxel), is a cornerstone of treatment to mitigate recurrence risk. However, these regimens disrupt endocrine homeostasis, precipitating ovarian dysfunction, hypoestrogenism, and skeletal demineralization. In premenopausal women, cyclophosphamide's gonadotoxicity induces POI, characterized by follicular depletion and hormonal imbalance, while in postmenopausal women, chemotherapy amplifies AI-induced bone loss. These perturbations necessitate a comprehensive understanding of underlying mechanisms, clinical manifestations, and mitigation strategies to optimize therapeutic outcomes and survivorship.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-5

RELEVANCE OF WORK

The global incidence of breast cancer exceeds 2.3 million cases annually, with node-positive non-luminal B subtypes requiring aggressive multimodal therapy. Advances in organ-preserving surgery and adjuvant treatments have elevated 5-year survival rates to over 85% for early-stage disease, yet the endocrine sequelae of chemotherapy remain a critical barrier to long-term quality of life. Premenopausal patients face fertility loss and menopausal symptoms, while postmenopausal patients are at heightened risk for osteoporosis and fractures. In luminal A breast cancer, the high endocrine responsiveness questions the necessity of chemotherapy in node-positive cases, whereas HER2-positive and TNBC necessitate cytotoxic therapy despite endocrine toxicities. This study synthesizes molecular, clinical, and epidemiological evidence to address these challenges, offering insights into personalized treatment algorithms, fertility preservation, and skeletal health management, thereby addressing a critical gap in survivorship care.

PURPOSE

This article aims to systematically elucidate the endocrine perturbations induced by adjuvant chemotherapy in patients with non-luminal B breast cancer (luminal A, HER2-positive, TNBC) with lymph node involvement post-organ-preserving surgery, delineating mechanisms, clinical implications, and evidence-based management strategies.

MATERIALS AND METHODS

This narrative review synthesizes literature from 2010 to 2025, retrieved from PubMed, Embase, Web of Science, and Cochrane Library. Search terms included “endocrine changes,” “adjuvant chemotherapy,” “non-luminal B breast cancer,” “luminal A,” “HER2-positive,” “triple-negative breast cancer,” “lymph node involvement,” “organ-preserving surgery,” “ovarian function,” “bone mineral density,” and “fertility preservation.” Inclusion criteria encompassed randomized controlled trials (RCTs), meta-analyses, and observational studies focusing on non-luminal B subtypes, adjuvant chemotherapy regimens, and endocrine outcomes in pre- and postmenopausal women. Exclusion criteria included studies on luminal B breast cancer, neoadjuvant settings, or those lacking endocrine-specific data. Data were extracted on chemotherapy regimens, POI incidence, hormonal profiles (FSH, estradiol, luteinizing hormone [LH]), BMD changes, and fertility outcomes. Statistical metrics (e.g., hazard ratios, relative risks) were prioritized from meta-analyses. Qualitative synthesis integrated molecular mechanisms, clinical outcomes, and therapeutic interventions, with two tables summarizing key findings.

RESULTS AND DISCUSSION

Adjuvant chemotherapy regimens for node-positive non-luminal B breast cancer, including CMF, anthracyclines, and taxanes, exert profound endocrine effects mediated by cytotoxic damage to endocrine tissues. Cyclophosphamide, an alkylating agent, induces DNA double-strand breaks in ovarian granulosa cells and oocytes, accelerating follicular atresia and reducing ovarian reserve. A meta-analysis by Lambertini et al. (2018) reported a POI incidence of 30.9% (95% CI: 26.2–35.8%) in premenopausal women receiving chemotherapy without ovarian suppression, compared to 14.1% (95% CI: 10.4–18.5%) with GnRH agonists (e.g., goserelin). This protective effect stems from GnRH agonists’ suppression of pituitary-ovarian axis activity, reducing follicular exposure to cytotoxic

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-5

agents. Chemotherapy-induced amenorrhea, observed in 76.9% of CMF-treated patients at 3 years, correlates with elevated FSH (>25 IU/L) and reduced estradiol (<20 pg/mL), precipitating menopausal symptoms (e.g., hot flashes, vaginal atrophy) and infertility.

In luminal A breast cancer, characterized by high ER/PR expression and low proliferative indices, the necessity of chemotherapy in node-positive cases is contentious. A meta-analysis by Li and Ma (2020) reported a hazard ratio (HR) of 1.86 (95% CI: 1.32–2.61) for overall survival with combined chemotherapy and endocrine therapy versus endocrine therapy alone, suggesting limited additive benefit. Tamoxifen, a selective ER modulator, or AIs (e.g., letrozole) effectively target ER signaling in luminal A tumors, with tamoxifen preserving ovarian function in premenopausal women but potentially stimulating ovulation, necessitating contraception. Gene expression assays, such as Oncotype DX and Breast Cancer Index (BCI), stratify recurrence risk, identifying low-risk patients who may forgo chemotherapy, thus minimizing endocrine toxicity.

HER2-positive and TNBC subtypes, lacking robust endocrine responsiveness, rely heavily on chemotherapy. Neoadjuvant trials demonstrate higher pathologic complete response (pCR) rates in these subtypes (20.8% for non-luminal HER2-negative vs. 7.9% for luminal HER2-negative), justifying cytotoxic therapy despite gonadotoxic risks. Cyclophosphamide-based regimens increase POI risk by 40–60% in women under 40, with dose-dependent effects (cumulative dose >7 g/m² heightens risk). Fertility preservation, including oocyte or embryo cryopreservation, is critical, with American Society of Clinical Oncology guidelines recommending pre-treatment counseling. Table 1 summarizes these endocrine outcomes across subtypes.

Table 1: Endocrine Outcomes of Chemotherapy in Non-Luminal B Breast Cancer

Breast Cancer Subtype	**Chemotherapy Regimen**	**Primary Endocrine Effect**	**Incidence/Impact**	**Mitigation Strategy**
Luminal A	CMF, Anthracyclines, Taxanes	POI, Amenorrhea	30.9% POI without GnRH; 76.9% amenorrhea at 3 years	GnRH agonists, endocrine therapy alone
HER2-positive	Anthracyclines, Taxanes, Anti-HER2 (e.g., Trastuzumab)	POI, Fertility Loss	40–60% POI in women <40	Oocyte/embryo cryopreservation
TNBC	Anthracyclines, Taxanes	POI, Estrogen Depletion	40–60% POI; 80% amenorrhea	GnRH agonists, fertility counseling
All Subtypes (Postmenopausal)	CMF, Anthracyclines, Taxanes + AIs	BMD Loss	5–7% BMD reduction in 1 year	Bisphosphonates, calcium/vitamin D

In postmenopausal women, chemotherapy exacerbates AI-induced bone loss by further suppressing residual estrogen production. AIs inhibit aromatase, reducing circulating estradiol to <10 pg/mL, leading to a 5–7% BMD reduction within 12 months and a 15–20% increased fracture risk.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-5

Bisphosphonates (e.g., zoledronic acid) counteract this, with RCTs showing a 2–3% BMD improvement after 2 years. Tamoxifen, conversely, preserves BMD in postmenopausal women but may exacerbate menopausal symptoms in premenopausal patients due to partial ER agonism. Table 2 outlines management strategies for these endocrine effects.

Table 2: Management Strategies for Chemotherapy-Induced Endocrine Effects

Endocrine Effect	Patient Population	Management Strategy	Evidence-Based Outcome	Reference
Premature Ovarian Insufficiency	Premenopausal	GnRH agonists (e.g., goserelin)	Reduces POI from 30.9% to 14.1%	Lambertini et al., 2018
Fertility Loss	Premenopausal	Oocyte/embryo cryopreservation	Preserves fertility in 80–90% of cases	ASCO Guidelines, 2020
Bone Loss	Postmenopausal	Bisphosphonates (e.g., zoledronic acid)	2–3% BMD improvement after 2 years	Gnant et al., 2016
Menopausal Symptoms	Pre/Postmenopausal	SSRIs, lifestyle interventions	50–70% symptom reduction	Ruddy et al., 2019

Molecularly, chemotherapy-induced ovarian damage involves oxidative stress and apoptosis in primordial follicles, mediated by upregulation of pro-apoptotic genes (e.g., Bax) and downregulation of anti-apoptotic genes (e.g., Bcl-2). In bone, chemotherapy and AIs disrupt osteoblast-osteoclast balance, increasing receptor activator of nuclear factor kappa-B ligand (RANKL) expression, promoting osteoclastogenesis. These mechanisms underscore the need for targeted interventions. Multidisciplinary care, integrating oncologists, endocrinologists, and reproductive specialists, is essential to address these complex sequelae, with ongoing trials exploring biomarkers (e.g., AMH for ovarian reserve) to predict endocrine toxicity.

CONCLUSION

Adjuvant chemotherapy for node-positive non-luminal B breast cancer post-organ-preserving surgery induces significant endocrine perturbations, including POI, hypoestrogenism, menopausal symptoms, and BMD loss. In premenopausal women, cyclophosphamide-based regimens drive follicular depletion, necessitating GnRH agonists and fertility preservation strategies. In postmenopausal women, AIs amplify chemotherapy-induced bone loss, requiring anti-resorptive therapies. Luminal A tumors may benefit from endocrine therapy alone in low-risk cases, guided by gene expression assays, while HER2-positive and TNBC require aggressive chemotherapy despite endocrine risks. The presented tables encapsulate these outcomes and interventions, highlighting the need for personalized, multidisciplinary care. Future research should focus on predictive biomarkers and novel therapies to mitigate endocrine toxicity, enhancing survivorship outcomes.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-5

REFERENCES

1. Li Y, Ma L. Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis. *World J Surg Oncol*. 2020;18:316. doi:10.1186/s12957-020-02073-6.

2. Lambertini M, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis. *J Clin Oncol*. 2018;36(19):1981-1990. doi:10.1200/JCO.2018.78.0855.

3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *Lancet*. 1998;351(9114):1451-1467. doi:10.1016/S0140-6736(97)11423-4.

4. Sgroi DC, et al. Comparison of the prognostic accuracy of the Breast Cancer Index, Oncotype DX, and IHC4 in ER-positive breast cancer. *J Clin Oncol*. 2013;31(15_suppl):537. doi:10.1200/JCO.2013.31.15_suppl.537.

5. Ruddy KJ, et al. Breast cancer survivorship: endocrine therapy and bone health. *J Clin Endocrinol Metab*. 2019;104(11):4983-4992. doi:10.1210/jc.2019-00577.

6. Burstein HJ, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline update. *J Clin Oncol*. 2019;37(5):423-438. doi:10.1200/JCO.18.01160.

7. Krop IE, et al. Neoadjuvant therapy in hormone receptor-positive/HER2-negative breast cancer. *Ann Oncol*. 2021;32(11):1383-1392. doi:10.1016/j.annonc.2021.08.1992.

8. Gnant M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from an international expert panel. *Ann Oncol*. 2016;27(3):379-390. doi:10.1093/annonc/mdv617.

9. Oktay K, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol*. 2020;38(19):2250-2261. doi:10.1200/JCO.20.00345.

10. Meirow D, et al. Chemotherapy-induced ovarian failure: mechanisms and clinical implications. *Fertil Steril*. 2010;94(4):1423-1429. doi:10.1016/j.fertnstert.2009.10.028.